Flavonoids as Strong Inhibitors of MAPK3: A Computational Drug Discovery Approach

Taherkhani, Amir; Khodadadi, Parita; Samie, Lida; Azadian, Zahra; Bayat, Zeynab

doi:https://doi.org/10.1155/2023/8899240

International Journal of Analytical Chemistry

On this page

Abstract Introduction Materials and Methods Results Discussion Conclusion Abbreviations Data Availability Ethical Approval Conflicts of Interest Authors’ Contributions Acknowledgments References Copyright Related Articles

Research Article | Open Access

Volume 2023 | Article ID 8899240 | https://doi.org/10.1155/2023/8899240

Flavonoids as Strong Inhibitors of MAPK3: A Computational Drug Discovery Approach

Amir Taherkhani,¹Parita Khodadadi,²Lida Samie,²Zahra Azadian,¹and Zeynab Bayat²

Academic Editor: Bishnu Regmi

Received26 Nov 2022

Revised17 Mar 2023

Accepted29 Mar 2023

Published14 Apr 2023

Abstract

Background. Mitogen-activated protein kinase 3 (MAPK3) mediates the onset, progression, metastasis, drug resistance, and poor prognosis in various malignancies, including glioma, liver, ovarian, thyroid, lung, breast, gastric, and oral cancers. Negative regulation of MAPK3 expression using miRNAs has led to therapeutic effects in cancer. Objectives. The present study performed molecular docking and dynamics simulation to identify potential MAPK3 inhibitors from natural flavonoids, possibly leading to drug development in cancer therapy. Methods. A computational drug discovery approach was performed using the AutoDock tool to identify potential MAPK3 inhibitors from 46 plant-based flavonoids. A cross-validation study was executed using the Schrödinger Maestro docking tool. Molecular dynamics (MD) was executed to evaluate the stability of docked poses between the top-ranked compounds and the MAPK3 catalytic domain. Interactions among the most potent MAPK3 inhibitors and residues within the receptor’s active site were studied using the BIOVIA Discovery Studio Visualizer before and after 100 ns MD simulations. Results. Kaempferol 3-rutinoside-4′-glucoside, kaempferol 3-rutinoside-7-sophoroside, rutin, and vicenin-2 exhibited a magnificent binding affinity to the receptor’s active site. In addition, the stability of the docked poses of these compounds seemed to be stable after ∼45 ns computer simulations. Conclusion. The present study suggests that kaempferol 3-rutinoside-4′-glucoside, kaempferol 3-rutinoside-7-sophoroside, rutin, and vicenin-2 could strongly bind to the MAPK3 catalytic site and could be assigned as a potent inhibitor for MAPK3. These findings may be helpful in the treatment of various cancers. However, further validation experiments are needed.

1. Introduction

Mitogen-activated protein kinase 3 (MAPK3), called extracellular signal-regulated kinase 1 (ERK1), is a critical ERK/MAPK pathway cell signaling molecule. It mediates the transmission of signals from a cell’s exterior to its interior. The ERK/MAPK pathway regulates apoptosis, cell proliferation, and migration [1, 2]. MAPK3 phosphorylates its downstream cytoplasmic protein, activating several nuclear transcription factors (e.g., c-Jun and c-fos) and participating in apoptosis and cell proliferation [3, 4]. The overexpression and/or hyperactivity of MAPK3 has been linked to the initiation, development, cancer cell migration, and drug resistance in various carcinomas, including liver, thyroid, lung, and gastric cancers [5]. Previously, Du et al. [6] reported that miR-143 upregulation reduced breast cancer cell proliferation by targeting MAPK3. Additionally, Cao et al. [5] demonstrated that the reduced miR-129 expression and MAPK3 overexpression were associated with cisplatin resistance in gastric cancer cells. MiR-129 overexpression also diminished the cell proliferation via downregulating MAPK3 leading to enhanced cell apoptosis. These results confirm the significant role of MAPK3 in tumorigenesis and drug resistance in different cancers.

Molecular docking analysis is a structural bioinformatics approach commonly used for drug discovery, identifying potential inhibitors for a given biological target. Molecular docking also unravels interaction modes between macromolecules and drug candidates [7, 8]. Molecular docking analysis includes three steps: macromolecule structure, preparation of small molecule structure, and evaluation of binding affinity between ligand and receptor [9]. Postdocking studies such as molecular dynamics (MD) analysis are frequently used to understand better ligands’ dynamic manner and stability within the receptors’ binding site (e.g., proteins’ active site). Moreover, MD enables assessing the flexibility of residues inside the catalytic site of proteins [10–12].

Flavonoids are secondary metabolites predominantly found in the plant kingdom, playing a significant role in plant development [13]. The basic structure of flavonoids has been shown in our previous study [14]. Generally, they comprise a C6-C3-C6 skeleton, in which the C6 rings are aromatic, and the C3 is a bridge linker [15]. Due to their high binding affinity to enzymes [16], flavonoids have demonstrated a wide range of pharmacological behaviors in medicine, including anticancer, antioxidant, anti-inflammatory, antiallergic, antibacterial, and antiviral properties [17, 18]. There is growing evidence suggesting the curative potential of flavonoids in different cancers such as breast [19], colorectal [20], oral [21], and lung cancers [22], as well as hepatocellular carcinoma [19].

The present study suggested that flavonoids may act as potential inhibitors of MAPK3 activity, leading to downregulating its downstream signaling pathways and reducing cell proliferation and migration. Therefore, we performed a molecular docking analysis to evaluate the binding affinity of several flavonoids to the MAPK3 active site. According to estimated inhibition constant values (Ki) between studied ligands and the protein active site, top-ranked MAPK3 inhibitors were introduced, interaction modes among top-ranked flavonoids and residues inside the MAPK3 catalytic site were analyzed, and the stability of the docked pose of the best MAPK3 inhibitor was studied by executing MD simulation. The present results might be beneficial in cancer treatment.

2. Materials and Methods

2.1. Structural Preparation of MAPK3 and Flavonoids

The three-dimensional structure of MAPK3 was downloaded at 1.4 Å X-ray resolution from the RCSB database [23], which is available at https://www.rcsb.org (PDB ID: 4QTB) [24]. The 4QTB file included two polypeptide chains: A and B. The total number of residues in each chain was checked using the Notepad++ tool. Accordingly, chains A and B included 351 and 348 residues, respectively. Therefore, chain A was selected for further analysis. Critical amino acids within the active site were identified by analyzing the two structure interactions among the 38Z (positive control inhibitor of the protein with a PDB ID of 24866313) and residues inside the active site of the protein using the BIOVIA Discovery Studio Visualizer version 19.1.0.18287, as well as reviewing the study by Chaikuad et al. [25]. Next, the 38Z molecule was eliminated from the PDB file, and energy optimization was executed via the Swiss-pdbViewer version 4.1.0, available at https://spdbv.unil.ch [26].

Previous studies have reported about 6000 flavonoids contributing to the colorful pigments of fruits, vegetables, and medicinal herbs [27]. The present study selected 46 flavonoids mainly found in commonly used fruits and vegetables, including onions, lettuce, kale, apples, tomatoes, berries, grapes, red grapes, red grapes, raspberries, strawberries, bilberries, merlot grapes, blueberries, and blackberries [27]. Therefore, 46 natural flavonoids were considered for identifying possible MAPK3 inhibitors, and the binding affinity of a standard drug (name: Purvalanol; PubChem ID: 448991; DrugBank ID: DB02733) to the active site of MAPK3 was regarded as a positive control inhibitor in this study. Structural preparation and energy minimization of flavonoids were explained in our previous study [28].

2.2. Molecular Docking

AutoDock 4.0 was used as a semiflexible docking tool [29, 30]. The software was installed in a windows-based computer system with the following features: installed memory: 32GB; processor: Intel Core i7; system type: 64-bit. Twenty-six residues were observed inside the active site of the receptor, including Tyr36, Ile48, Ala52, Tyr53, Lys54, Val56, Ser57, Tyr64, Ala69, Lys71, Ile73, Tyr81, Arg84, Thr85, Gln105, Asp106, Leu107, Lys114, Asp123, Met125, Asp128, Lys131, Cys166, Asp167, Leu173, and Asp184. To avoid missing any atoms related to the residues cooperated in the MAPK3 active site, the grid box was set to 84, 60, and 70, pointing in x, y, and z coordinates, respectively, with a spacing of 0.375 Å. The grid box centers were 33.335 Å, 55.015 Å, and 49.3 Å for X, Y, and Y directions, respectively. Fifty conformations were constructed for each flavonoid using the Lamarckian genetic algorithm [31] and ranked based on their estimated binding energies.

2.3. Cross-Validation Study

The most potent MAPK3 inhibitors achieved from the AutoDock tool were selected for cross-validation study. In this regard, the Schrödinger Maestro docking tool version 10.2 was used to calculate the docking scores [32, 33]. The lowest dock score (Glide score) was assigned as the best-docked model for each component. Furthermore, the prime MM-GBSA approach was utilized to indicate the relative binding energies [34].

2.4. Molecular Dynamics

MD was executed in 100 ns (1,00,000 ps) simulations by Discovery Studio Client software version 16.1.0.15350 to evaluate the stability of the docked poses between the top-ranked flavonoids, based on the AutoDock tool and Schrodinger Maestro docking software and MAPK3 active site. Advanced settings for MD simulation are mentioned in our previous report [28]. Furthermore, the root mean square fluctuation (RMSF) of MAPK3 residues and the time evolution of root mean square deviation (RMSD) of the receptor backbone atoms complexed with the top-ranked flavonoids were analyzed. BIOVIA Discovery Studio Visualizer 19.1.0.18287 was used to unravel interactions between top-ranked flavonoids and residues inside the MAPK3 active site and to illustrate two- and three-dimensional views of their docked poses.

2.5. Pharmacokinetic and Toxicology Assessment

The SwissADME online web server, available at https://www.swissadme.ch/ [35], evaluated the selected flavonoids’ absorption, distribution, metabolism, and excretion (ADME). Furthermore, the ligands’ Lethal Dose 50 (LD50) was predicted using the ProTox-IIweb server available from https://tox.charite.de/protox_II/ [36].

3. Results

3.1. Binding Affinity Assessment Using AutoDock

According to the virtual screening analysis achieved by AutoDock 4.0, four and 32 compounds demonstrated Ki values at the micromolar (uM) and nanomolar (nM) scales, respectively. Besides, it was estimated that nine compounds, including orientin, kaempferol 3-rutinoside-7-sophoroside, rutin, isoquercitrin, vicenin-2, amentoflavone, quercetin-3-rhamnoside, nicotiflorin, and sophoraflavanone G, could potentially bind to the MAPK3 active site at the picomolar (pM) scale. Also, a salient binding affinity was observed between kaempferol 3-rutinoside-4′-glucoside (PubChem ID: 44258844) and MAPK3 catalytic site with the Ki and ΔG_binding values of 731.68 femtomolar (fM) and 16.65 kcal/mol, respectively. Therefore, the present study calculated the Ki value for ten compounds at either pM or fM concentrations. These flavonoids were considered top-ranked MAPK3 inhibitors among the studied flavonoids based on the AutoDock tool. Figure 1 demonstrates the chemical structures of these flavonoids and purvalanol. The ΔG_binding value between purvalanol and MAPK3 active site was estimated as 8.53 kcal/mol. Accordingly, 39 flavonoids demonstrated a higher binding affinity to the MAPK3 catalytic site than the positive control inhibitor. Figure 2 presents ΔG_binding values between top-ranked flavonoids achieved from the AutoDock tool, the standard drug, and MAPK3 active site. The estimated binding energies and Ki values for 46 flavonoids and the control inhibitor in this study are presented in Table 1. Furthermore, the details of energies between top-ranked inhibitors and MAPK3 catalytic domain are shown in Table 2.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

Figure 2

Estimated binding energies between these study’s most potent MAPK3 inhibitors compared to the standard drug (purvalanol) achieved from the AutoDock tool. The x-axis illustrates the compound’s names, and the y-axis shows their estimated binding energies (kcal/mol). The green diamond presents the purvalanol, while yellow, orange, and red spots represent flavonoids with inhibition constant values at nanomolar, picomolar, and femtomolar scales, respectively. MAPK3, mitogen-activated protein kinase 3.

3.2. Cross-Validation Study Using Schrödinger Maestro Docking Tool

Cross-validation analysis was performed for kaempferol 3-rutinoside-4′-glucoside, orientin, kaempferol 3-rutinoside-7-sophoroside, rutin, isoquercitrin, vicenin-2, amentoflavone, quercetin-3-rhamnoside, nicotiflorin, sophoraflavanone G, and purvalanol. According to the results achieved from the Schrödinger Maestro docking tool, four metabolites, including kaempferol 3-rutinoside-4′-glucoside, kaempferol 3-rutinoside-7-sophoroside, rutin, and vicenin-2, demonstrated docking scores <10 kcal/mol. These components assigned the most potent MAPK3 inhibitors based on the AutoDock 4.0 and Schrödinger Maestro docking tool version 10.2. Therefore, MD was executed to evaluate the strength of their docked poses in 100 ns computer simulation. Table 3 presents the docking scores and MM-GBSA results calculated by the Schrödinger Maestro docking tool. The prime MM-GBSA analysis calculates the ΔG_bindingvalue between ligands and macromolecules.

3.3. Stability of the Docked Poses

Regarding MD analysis, the docked poses between kaempferol 3-rutinoside-4′-glucoside, kaempferol 3-rutinoside-7-sophoroside, rutin, vicenin-2, and MAPK3 active site were stable after ∼45 ns computer simulations. Figure 3 demonstrates RMSF and RMSD for MAPK3 backbone atoms complexed with top-ranked flavonoids in this study and the standard drug. Figure 4 illustrates the superimposed structures of top-ranked complexes before and after MD simulations.

(a)

(b)

(a)

(b)

(c)

(d)

(e)

BIOVIA Discovery Studio Visualizer 19.1.0.18287 unraveled hydrogen bonds and hydrophobic interactions between top-ranked flavonoids (based on the AutoDock tool and Schrodinger Maestro docking software), purvalanol, and the enzyme’s active site (Figure 5 and Table 4). The number of H bonds was increased after 100 ns computer simulations for kaempferol 3-rutinoside-4′-glucoside, kaempferol 3-rutinoside-7-sophoroside, rutin, and vicenin-2.

(a)

(b)

(c)

(d)

(e)

3.4. ADMET Assessment

SwissADME provides valuable information related to the pharmacokinetic features of compounds. The following ADME was predicted for 46 flavonoids studies in the present study: gastrointestinal (GI) and blood–brain barrier (BBB) permeability, P-gp (P-glycoprotein) substrate, cytochrome P-450 inhibition, and skin permeation coefficient (kp). Rutin and vicenin-2 revealed more appropriate ADME among top-ranked flavonoids. Besides, none of the compounds demonstrated considerable toxicity. Table 5 lists the results of ADME and the toxicity of the compounds.

4. Discussion

MAPK3 is a serine/threonine kinase involved in the phosphorylation and translocation of several cytosolic proteins into the nucleus, leading to the dysregulation of several vital pathways and biological processes associated with apoptosis and cell proliferation [37]. Elevated expression and/or activity of MAPK3 is linked to the onset, development, drug resistance, and metastasis of various carcinomas such as ovarian cancer [38], glioma [39], lung cancer [40], and breast cancer [41]. Therefore, the present study executed a computational drug discovery approach to identify potential MAPK3 inhibitors from natural flavonoids, which have widely exhibited anticanter effects [42].

According to the AutoDock results, kaempferol 3-rutinoside-4′-glucoside demonstrated the highest binding affinity to the MAPK3 active site (ΔG_binding = 16.56 kcal/mol; Ki = 731.68 fM) followed by orientin, kaempferol 3-rutinoside-7-sophoroside, rutin, isoquercitrin, vicenin-2, amentoflavone, nicotiflorin, quercetin-3-rhamnoside, and sophoraflavanone G. The cross-validation study also confirmed the high affinity of binding between kaempferol 3-rutinoside-4′-glucoside, kaempferol 3-rutinoside-7-sophoroside, rutin, vicenin-2, and MAPK3 active site. Therefore, these metabolites were considered the most potent MAPK3 inhibitors from the studied flavonoids.

Kaempferol 3-rutinoside-4′-glucoside is isolated from the fruits of Lyciumruthenicum Murr [43] and the leaves of Agave sisalana Perrine ex Engelm [44]. This compound demonstrated six H-bonds with Ile48, Glu50, Ala52, Lys131, Ser170, and Asp184 within the MAPK3 catalytic site before MD simulation. This flavonoid also exhibited 15 hydrogen and one hydrophobic interaction with Ala52, Tyr53, Ile48, Arg84, Asp128, Asp166, Lys168, Ser170, and Asn171, after 100 ns MD simulation. In addition, salient binding affinities were estimated between kaempferol 3-rutinoside-7-sophoroside, kaempferol 7-O-glucoside, and MAPK3 active site with the ΔG_binding value of 15.49 and 11.87 kcal/mol, respectively.

Kaempferol 3-rutinoside-7-sophoroside formed five hydrogen bonds with the Gly49, Ala52, Arg84, Asp166, and Asp184 located in the MAPK3 active site before MD simulation. This compound formed ten H bonds with the Tyr47, Glu50, Gly51, Arg84, Asp128, Lys131, Asp166, and Asp184, after 100 ns MD simulations. Besides, kaempferol showed a lower binding affinity to the MAPK3 catalytic site compared to that of its glycosylated forms with a ΔG_binding value of 8.5 kcal/mol, indicating a positive correlation between binding sugar moieties to the rings A, B, and C and enhancing binding affinity between kaempferol and MAPK3 active site. According to a previous report [14], kaempferol exhibited a considerable binding affinity to the matrix metalloproteinase 8 (MMP8) catalytic domain with a ΔG_binding value of 10.88 kcal/mol. Due to the critical role of MMP8 [45] and MAPK3 in cancer development and metastasis, kaempferol and its glycosylated forms could be considered drug candidates for cancer therapy.

Kaempferol is a yellow flavonoid [46] mainly found in apples, tomatoes, grapes, pine, green tea, and angelica [47]. Antioxidant and anti-inflammatory properties of kaempferol [46] may lead to therapeutic effects in various cancers by regulating cell cycle, apoptosis, metastasis, and angiogenesis [48]. Fouzder et al. [49] demonstrated that kaempferol diminished Nrf2 at mRNA and protein levels in nonsmall cell lung cancer cells, leading to the downregulation of Nrf2 downstream genes, including GST, AKR1C1, HO1, and NQO1, resulting in cancer cells sensitive to apoptosis. Pan et al. [50] executed an experimental study to examine the effects of kaempferol on rheumatoid arthritis (RA) in vitro and in vivo. The authors examined the cell migration and invasion using scratch assays and the Boyden chamber approaches, respectively. The cytoskeletal reorganization of RA fibroblast-like synoviocytes was tested using immunofluorescence staining. Real-time PCR and western blotting assays were used to examine the MMP expression levels. Pan et al. [50] reported that kaempferol diminished cell migration and invasion by downregulating the MAPK pathway, reduced the MMP expression, and inhibited the actin reorganization in RA FLSs. Huang et al. [51] demonstrated that kaempferol significantly inhibited the expression of several genes mediating inflammatory response, including interleukin (IL)-1β, cyclooxygenase-2, and nitric oxide synthase. Furthermore, kaempferol diminished collagen II degradations by inhibiting MMP1, MMP3, and MMP13 expression. In addition, kaempferol downregulated the p38 MAPK pathway. Taken together, Huang et al. [51] introduced kaempferol as a compound with therapeutic effects in osteoarthritis.

Orientin was this study’s second leading potential MAPK3 inhibitor with the ΔG_binding and Ki values of 15.98 kcal/mol and 1.92 pM, respectively. This flavonoid exhibited seven hydrogen and two hydrophobic interactions with the Gly49, Tyr53, Glu50, Val56, Asp128, Ser170, and Asn171 inside the MAPK3 catalytic site. Khamverdi et al. [52] also reported a considerable binding affinity between orientin and another protein kinase named glycogen synthase kinase 3 beta (GSK3B) with the criteria of ΔG_binding and Ki values of 9.43 kcal/mol and 123.19 nM, respectively. Moreover, orientin has demonstrated a high affinity of binding to the MMP8 (ΔG_binding = 10.56 kcal/mol) [14] and MMP13 (ΔG_binding = 10.5 kcal/mol) [53] catalytic sites. The role of MMP13 in cancer progression [54] and metastasis [55] is evident. Therefore, orientin could be assigned as a potential drug candidate for cancer treatment with inhibitory effects against proteins involved in cancer onset, development, and metastasis.

Orientin is predominantly found in dayflower, millet, passion fruit, and pigeon pea leaves [56]. Several pharmacological features have been reported for orientin, such as antioxidant, anti-inflammatory, antimicrobial, and radio-protective effects [57]. Kim et al. [58] demonstrated that orientin inhibited the invasive behavior of breast cancer cells via downregulating MMP9 and interleukin (IL-8) expression. Furthermore, Tian et al. [59] reported that orientin reduced cell proliferation and enhanced the apoptosis process in T24 human transitional cell bladder carcinoma cells in vitro by inhibiting nuclear factor-kappaB (NF-κB).

Wu et al. [60] demonstrated that mulberry ethanol extract (MBE) and rutin (the most abundant phenolic component in MBE) significantly reduced the expression of several genes mediating the MAPK pathway, including ERK, JNK, p38, and caspase-3, leading to reduced oxidative stress in gastric mucosal epithelial cells. This was done using the quantitative PCR method. Rutin demonstrated five hydrogen and nine hydrophobic interactions with the Ile48, Tyr53, Lys71, Tyr130, Lys131, Val56, Leu173, Cys183, and Asp184 before MD simulation. Besides, rutin exhibited 12 hydrogen and two hydrophobic interactions with the Ile48, Glu50, Gly51, Val56, Lys71, Glu122, Thr127, Asp128, Lys131, Ser170, Asn171, and Asp184 within the MAPK3 active site after 100 ns MD simulations.

Chen et al. [61] reported that vicenin-3 considerably reduced the expression levels of nitric oxide, prostaglandin E2, MMP1, MMP3, MMP13, and A disintegrin-like and metalloproteinase with thrombospondin motifs (ADAMTS). Moreover, vicenin-3 inhibited the p38 MAPK signaling pathway; the results were similar to that of SB203580 (a well-known p38 MAPK inhibitor). The present study evaluated the binding affinity between vicenin-2 and MAPK3 active site. Vicenin-2 showed seven hydrogen and five hydrophobic interactions with the Tyr53, Val56, Ala69, Ala128, Lys131, Asn171, Leu173, Cys183, and Asp184 before MD analysis. Furthermore, this compound illustrated ten hydrogen and four hydrophobic interactions with the Glu50, Lys71, Gln122, Asp123, Thr127, Asp128, Lys131, Ser170, and Cys183 after 100 ns computer simulations.

By analyzing the binding affinities between top-ranked MAPK3 inhibitors achieved from the AutoDock tool in this study and comparing the results with their corresponding structures, the following notes are suggested:(1)By comparing the results of kaempferol with its glycosylated forms, it might be suggested that binding a sugar moiety (or sugar moieties) to the basic structure of flavonoids elevates the binding affinity of the compound to MAPK3(2)By analyzing the ΔG_binding values between kaempferol 3-rutinoside-4′-glucoside, kaempferol 3-rutinoside-7-sophoroside, rutin, vicenin-2, and MAPK3 catalytic site, it could be hypothesized that binding a disaccharide to the ring C or two monosaccharides to the ring A considerably elevates the binding affinity of the compound to the MAPK3

5. Conclusion

In conclusion, the binding affinity of 46 flavonoids to the MAPK3 catalytic domain was estimated using the AutoDock tool. Thirty-nine flavonoids exhibited a higher binding affinity to the MAPK3 active site than the standard drug. A cross-validation study was executed on top-ranked flavonoids based on the AutoDock software. Kaempferol 3-rutinoside-4′-glucoside, kaempferol 3-rutinoside-7-sophoroside, rutin, and vicenin-2 exhibited excellent binding affinity using AutoDock 4.0 and Schrödinger Maestro docking tool. Also, these flavonoids' docked poses seemed stable after ∼45 ns MD simulations. The present study suggests kaempferol 3-rutinoside-4′-glucoside, kaempferol 3-rutinoside-7-sophoroside, rutin, and vicenin-2 as potent inhibitors of MAPK3. These findings may be helpful in the treatment of various cancers. However, in vitro, in vivo, and clinical trial studies are needed.

Abbreviations

MAPK3:	Mitogen-activated protein kinase 3
ERK1:	Extracellular signal-regulated kinase 1
Ki:	Inhibition constant
RMSF:	Root mean square fluctuation
RMSD:	Root mean square deviation
MD:	Molecular dynamics
μM:	Micromolar
nM:	Nanomolar
pM:	Picomolar
ns:	Nanosecond.

Data Availability

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethical Approval

The present study was approved by the Ethics Committee of Hamadan University of Medical Sciences, Hamadan, Iran (ethics no.IR.UMSHA.REC.1401.259).

Conflicts of Interest

The authors declare that they have no conflicts of interests.

Authors’ Contributions

AT, ZB, and LS designed the study. Docking operations with the AutoDock tool were conducted by PK. ZA executed the cross-validation analysis. MD simulations were performed by AT. The results were analyzed and discussed by AT, ZB, and LS. AT wrote the manuscript. ZB and LS edited the manuscript. All authors read and approved the final version of the manuscript.

Acknowledgments

The authors thank the Deputy of Research and Technology, Research Center for Molecular Medicine, and Dental Research Center, Hamadan University of Medical Sciences, Hamadan-Iran, for their support.

References

P. Bargagna‐Mohan, A. Ishii, L. Lei et al., “Sustained activation of ERK1/2 MAPK in Schwann cells causes corneal neurofibroma,” Journal of Neuroscience Research, vol. 95, no. 9, pp. 1712–1729, 2017.
View at: Publisher Site | Google Scholar
E. Jin, S. Han, M. Son, and S.-W. Kim, “Cordyceps bassiana inhibits smooth muscle cell proliferation via the ERK1/2 MAPK signaling pathway,” Cellular and Molecular Biology Letters, vol. 21, no. 1, pp. 24–28, 2016.
View at: Publisher Site | Google Scholar
Y.-L. Hao, H.-C. Fang, H.-L. Zhao et al., “The role of microRNA-1 targeting of MAPK3 in myocardial ischemia-reperfusion injury in rats undergoing sevoflurane preconditioning via the PI3K/Akt pathway,” American Journal of Physiology - Cell Physiology, vol. 315, no. 3, pp. C380–C388, 2018.
View at: Publisher Site | Google Scholar
L. A. McGinnis, H. J. Lee, D. N. Robinson, and J. P. Evans, “MAPK3/1 (ERK1/2) and myosin light chain kinase in mammalian eggs affect myosin-II function and regulate the metaphase II state in a calcium-and zinc-dependent manner,” Biology of Reproduction, vol. 92, no. 6, pp. 146–114, 2015.
View at: Publisher Site | Google Scholar
H. Y. Cao, C. H. Xiao, H. J. Lu et al., “MiR-129 reduces CDDP resistance in gastric cancer cells by inhibiting MAPK3,” European Review for Medical and Pharmacological Sciences, vol. 24, no. 22, Article ID 11468, 2020.
View at: Publisher Site | Google Scholar
Y. Du, J. Zhang, Y. Meng, M. Huang, W. Yan, and Z. Wu, “MicroRNA-143 targets MAPK3 to regulate the proliferation and bone metastasis of human breast cancer cells,” AMB Express, vol. 10, no. 1, p. 134, 2020.
View at: Publisher Site | Google Scholar
D. B. Kitchen, H. Decornez, J. R. Furr, and J. Bajorath, “Docking and scoring in virtual screening for drug discovery: methods and applications,” Nature Reviews Drug Discovery, vol. 3, no. 11, pp. 935–949, 2004.
View at: Publisher Site | Google Scholar
L. Pinzi and G. Rastelli, “Molecular docking: shifting paradigms in drug discovery,” International Journal of Molecular Sciences, vol. 20, no. 18, p. 4331, 2019.
View at: Publisher Site | Google Scholar
M. H. A. Al-Jumaili and M. K. Y. Al Hdeethi, “Study of selected flavonoid structures and their potential activity as breast anticancer agents,” Cancer Informatics, vol. 20, Article ID 11769351211055160, 2021.
View at: Publisher Site | Google Scholar
M. De Vivo, M. Masetti, G. Bottegoni, and A. Cavalli, “Role of molecular dynamics and related methods in drug discovery,” Journal of Medicinal Chemistry, vol. 59, no. 9, pp. 4035–4061, 2016.
View at: Publisher Site | Google Scholar
J. D. Durrant and J. A. McCammon, “Molecular dynamics simulations and drug discovery,” BMC Biology, vol. 9, no. 1, pp. 71–79, 2011.
View at: Publisher Site | Google Scholar
M. Karplus and J. A. McCammon, “Molecular dynamics simulations of biomolecules,” Nature Structural Biology, vol. 9, no. 9, pp. 646–652, 2002.
View at: Publisher Site | Google Scholar
W. Liu, Y. Feng, S. Yu et al., “The flavonoid biosynthesis network in plants,” International Journal of Molecular Sciences, vol. 22, no. 23, Article ID 12824, 2021.
View at: Publisher Site | Google Scholar
A. Taherkhani, S. Moradkhani, A. Orangi, A. Jalalvand, and Z. Khamverdi, “Molecular docking study of flavonoid compounds for possible matrix metalloproteinase-13 inhibition,” Journal of Basic and Clinical Physiology and Pharmacology, vol. 32, no. 6, pp. 1105–1119, 2021.
View at: Publisher Site | Google Scholar
S. Moradkhani, A. Farmani, M. Saidijam, and A. Taherkhani, “COVID-19: docking-based virtual screening and molecular dynamics study to identify potential SARS-CoV-2 spike protein inhibitors from plant-based phenolic compounds,” Acta Virologica, vol. 65, no. 3, pp. 288–302, 2021.
View at: Publisher Site | Google Scholar
M. Muchtaridi, M. Fauzi, N. K. Khairul Ikram, A. Mohd Gazzali, and H. A. Wahab, “Natural flavonoids as potential angiotensin-converting enzyme 2 inhibitors for anti-SARS-CoV-2,” Molecules, vol. 25, no. 17, Article ID 2517, 2020.
View at: Publisher Site | Google Scholar
A. Ekalu and J. D. Habila, “Flavonoids: isolation, characterization, and health benefits,” Beni-Suef University Journal of Basic and Applied Sciences, vol. 9, no. 1, pp. 45–14, 2020.
View at: Publisher Site | Google Scholar
M. Singh, M. Kaur, and O. Silakari, “Flavones: an important scaffold for medicinal chemistry,” European Journal of Medicinal Chemistry, vol. 84, pp. 206–239, 2014.
View at: Publisher Site | Google Scholar
C. Bailly, “Molecular and cellular basis of the anticancer activity of the prenylated flavonoid icaritin in hepatocellular carcinoma,” Chemico-Biological Interactions, vol. 325, Article ID 109124, 2020.
View at: Publisher Site | Google Scholar
Y. Gu, J. Yu, C. Ding et al., “Flavonoid GL-V9 suppresses invasion and migration of human colorectal cancer cells by inhibiting PI3K/Akt and MMP-2/9 signaling,” Journal of Cancer, vol. 12, no. 15, pp. 4542–4551, 2021.
View at: Publisher Site | Google Scholar
H. Y. Han, H. J. Kim, S. H. Jeong et al., “The flavonoid jaceosidin from artemisia princeps induces apoptotic cell death and inhibits the akt pathway in oral cancer cells,” Evid Based Complement Alternat Med, vol. 13, Article ID 5765047, 2018.
View at: Publisher Site | Google Scholar
H. R. Kang, J. Y. Moon, M. K. Ediriweera, Y. W. Song, M. Cho, and D. Kasiviswanathan, “Dietary flavonoid myricetin inhibits invasion and migration of radioresistant lung cancer cells (A549-IR) by suppressing MMP-2 and MMP-9 expressions through inhibition of the FAK-ERK signaling pathway,” vol. 8, no. 4, pp. 2059–2067, 2020.
View at: Google Scholar
S. K. Burley, C. Bhikadiya, C. Bi et al., “RCSB Protein Data Bank: powerful new tools for exploring 3D structures of biological macromolecules for basic and applied research and education in fundamental biology, biomedicine, biotechnology, bioengineering and energy sciences,” Nucleic Acids Research, vol. 49, no. 1, pp. D437–D451, 2021.
View at: Publisher Site | Google Scholar
C. C. Chen and O. Herzberg, “Inhibition of β-lactamase by clavulanate: trapped intermediates in cryocrystallographic studies,” Journal of Molecular Biology, vol. 224, no. 4, pp. 1103–1113, 1992.
View at: Publisher Site | Google Scholar
A. Chaikuad, E. M C Tacconi, J. Zimmer et al., “A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics,” Nature Chemical Biology, vol. 10, no. 10, pp. 853–860, 2014.
View at: Publisher Site | Google Scholar
N. Guex, M. C. Peitsch, and T. Schwede, “Automated comparative protein structure modeling with SWISS‐MODEL and Swiss‐PdbViewer: a historical perspective,” Electrophoresis, vol. 30, no. 1, pp. S162–S173, 2009.
View at: Publisher Site | Google Scholar
A. N. Panche, A. D. Diwan, and S. R. Chandra, “Flavonoids: an overview,” Journal of nutritional science, vol. 5, p. 47, 2016.
View at: Publisher Site | Google Scholar
M. Masumi, F. Noormohammadi, F. Kianisaba, F. Nouri, M. Taheri, and A. Taherkhani, “Methicillin-resistant Staphylococcus aureus: docking-based virtual screening and molecular dynamics simulations to identify potential penicillin-binding protein 2a inhibitors from natural flavonoids,” International journal of microbiology, vol. 2022, Article ID 9130700, 14 pages, 2022.
View at: Publisher Site | Google Scholar
G. M. Morris, R. Huey, and A. J. Olson, “Using autodock for ligand‐receptor docking,” Current protocols in bioinformatics, vol. 8, no. 1, pp. 11–14, 2008.
View at: Publisher Site | Google Scholar
O. Trott and A. J. Olson, “AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading,” Journal of Computational Chemistry, vol. 31, no. 2, pp. 455–461, 2010.
View at: Publisher Site | Google Scholar
G. M. Morris, R. Huey, W. Lindstrom et al., “AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility,” Journal of Computational Chemistry, vol. 30, no. 16, pp. 2785–2791, 2009.
View at: Publisher Site | Google Scholar
R. A. Friesner, R. B. Murphy, M. P. Repasky et al., “Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein− ligand complexes,” Journal of Medicinal Chemistry, vol. 49, no. 21, pp. 6177–6196, 2006.
View at: Publisher Site | Google Scholar
K. Zhu, K. W. Borrelli, J. R. Greenwood et al., “Docking covalent inhibitors: a parameter free approach to pose prediction and scoring,” Journal of Chemical Information and Modeling, vol. 54, no. 7, pp. 1932–1940, 2014.
View at: Publisher Site | Google Scholar
Z. Azadian, S. Hosseini, Z. P. Dizjikan et al., “Computational and in vitro validation of cardiogenic induction of quercetin on adipose‐derived mesenchymal stromal cells through the inhibition of Wnt and non‐Smad‐dependent TGF‐β pathways,” Journal of Cellular Biochemistry, vol. 123, no. 2, pp. 450–468, 2022.
View at: Publisher Site | Google Scholar
A. Daina, O. Michielin, and V. Zoete, “SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules,” Scientific Reports, vol. 7, no. 1, Article ID 42717, 2017.
View at: Publisher Site | Google Scholar
P. Banerjee, A. O. Eckert, A. K. Schrey, and R. Preissner, “ProTox-II: a webserver for the prediction of toxicity of chemicals,” Nucleic Acids Research, vol. 46, no. 1, pp. W257–W263, 2018.
View at: Publisher Site | Google Scholar
Z. Chen, Y. Gao, R. Hou et al., “MicroRNA-206 facilitates gastric cancer cell apoptosis and suppresses cisplatin resistance by targeting MAPK2 signaling pathway,” European Review for Medical and Pharmacological Sciences, vol. 23, no. 1, pp. 171–180, 2019.
View at: Publisher Site | Google Scholar
M. Kielbik, D. Krzyzanowski, B. Pawlik, and M. Klink, “Cisplatin-induced ERK1/2 activity promotes G1 to S phase progression which leads to chemoresistance of ovarian cancer cells,” Oncotarget, vol. 9, no. 28, pp. 19847–19860, 2018.
View at: Publisher Site | Google Scholar
B. Li, Y. Liu, A. Sun, L. Huan, H. Li, and D. Liu, “MiR-130b functions as a tumor promoter in glioma via regulation of ERK/MAPK pathway,” European Review for Medical and Pharmacological Sciences, vol. 21, no. 12, pp. 2840–2846, 2017.
View at: Google Scholar
H. Dou, Z. Yan, M. Zhang, and X. Xu, “APRIL promotes non-small cell lung cancer growth and metastasis by targeting ERK1/2 signaling,” Oncotarget, vol. 8, no. 65, pp. 109289–109300, 2017.
View at: Publisher Site | Google Scholar
J.-Y. Ho, R.-J. Hsu, C.-H. Wu et al., “Reduced miR-550a-3p leads to breast cancer initiation, growth, and metastasis by increasing levels of ERK1 and 2,” Oncotarget, vol. 7, no. 33, pp. 53853–53868, 2016.
View at: Publisher Site | Google Scholar
P. Batra and A. K. Sharma, “Anti-cancer potential of flavonoids: recent trends and future perspectives,” Biotech, vol. 3, no. 6, pp. 439–459, 2013.
View at: Publisher Site | Google Scholar
Q. Jing-jing, Y. Yong-ming, W. Cheng-xiang, and C. Yong-xian, “Compounds from lycium ruthenicum,” NATURAL PRODUCT RESEARCH AND DEVELOPMENT, vol. 30, no. 3, p. 345, 2018.
View at: Google Scholar
P. Y. Chen, Y. C. Kuo, C. H. Chen, Y. H. Kuo, and C. K. Lee, “Isolation and immunomodulatory effect of homoisoflavones and flavones from agave sisalana perrine ex Engelm,” Molecules, vol. 14, no. 5, pp. 1789–1795, 2009, https://www.mdpi.com/1420-3049/14/5/1789.
View at: Publisher Site | Google Scholar
P. Van Lint and C. Libert, “Matrix metalloproteinase-8: cleavage can be decisive,” Cytokine & Growth Factor Reviews, vol. 17, no. 4, pp. 217–223, 2006.
View at: Publisher Site | Google Scholar
C. Rice-Evans, “Flavonoid antioxidants,” Current Medicinal Chemistry, vol. 8, no. 7, pp. 797–807, 2001.
View at: Publisher Site | Google Scholar
S. Kim, K. Y. Kim, C. S. Han et al., “Simultaneous analysis of six major compounds in Osterici Radix and Notopterygii Rhizoma et Radix by HPLC and discrimination of their origins from chemical fingerprint analysis,” Archives of Pharmacal Research, vol. 35, no. 4, pp. 691–699, 2012.
View at: Publisher Site | Google Scholar
S.-H. Kim and K.-C. Choi, “Anti-cancer effect and underlying mechanism (s) of kaempferol, a phytoestrogen, on the regulation of apoptosis in diverse cancer cell models,” Toxicological Research, vol. 29, no. 4, pp. 229–234, 2013.
View at: Publisher Site | Google Scholar
C. Fouzder, A. Mukhuty, and R. Kundu, “Kaempferol inhibits Nrf2 signalling pathway via downregulation of Nrf2 mRNA and induces apoptosis in NSCLC cells,” Archives of Biochemistry and Biophysics, vol. 697, Article ID 108700, 2021.
View at: Publisher Site | Google Scholar
D. Pan, N. Li, Y. Liu et al., “Kaempferol inhibits the migration and invasion of rheumatoid arthritis fibroblast-like synoviocytes by blocking activation of the MAPK pathway,” International Immunopharmacology, vol. 55, pp. 174–182, 2018.
View at: Publisher Site | Google Scholar
X. Huang, Q. Pan, Z. Mao et al., “Kaempferol inhibits interleukin-1β stimulated matrix metalloproteinases by suppressing the MAPK-associated ERK and P38 signaling pathways,” Molecular Medicine Reports, vol. 18, no. 3, pp. 2697–2704, 2018.
View at: Publisher Site | Google Scholar
Z. Khamverdi, Z. Mohamadi, and A. Taherkhani, “Molecular docking and dynamics simulation of natural phenolic compounds with GSK-3β: a putative target to combat mortality in patients with COVID-19,” Recent Advances in Inflammation & Allergy Drug Discovery, vol. 15, no. 1, pp. 16–34, 2022.
View at: Publisher Site | Google Scholar
A. Taherkhani, A. Orangi, S. Moradkhani, and Z. Khamverdi, “Molecular docking analysis of flavonoid compounds with matrix metalloproteinase-8 for the identification of potential effective inhibitors,” Letters in Drug Design and Discovery, vol. 18, no. 1, pp. 16–45, 2021.
View at: Publisher Site | Google Scholar
Y. Wang, X. Pei, C. Wang, and Z. Tan, “lncRNA-GPAND promotes gastric cancer progression via RUNX2 and MMP13,” 2021, https://www.researchgate.net/publication/356627464_lncRNA-GPAND_Promotes_Gastric_Cancer_Progression_via_RUNX2_and_MMP13.
View at: Google Scholar
S. W. Wang, H. C. Tai, C. H. Tang et al., “Melatonin impedes prostate cancer metastasis by suppressing MMP‐13 expression,” Journal of Cellular Physiology, vol. 236, no. 5, pp. 3979–3990, 2021.
View at: Publisher Site | Google Scholar
K. Y. Lam, A. P. K. Ling, R. Y. Koh, Y. P. Wong, and Y. H. Say, “A review on medicinal properties of orientin,” Advances in pharmacological sciences, vol. 2016, Article ID 4104595, 9 pages, 2016.
View at: Publisher Site | Google Scholar
E. Bouchouka, A. Djilani, and A. Bekkouche, “Antibacterial and antioxidant activities of three endemic plants from Algerian Sahara,” Acta Scientiarum Polonorum Technologia Alimentaria, vol. 11, no. 1, pp. 61–65, 2012.
View at: Google Scholar
S.-J. Kim, T.-H. Pham, Y. Bak, H.-W. Ryu, S.-R. Oh, and D.-Y. Yoon, “Orientin inhibits invasion by suppressing MMP-9 and IL-8 expression via the PKCα/ERK/AP-1/STAT3-mediated signaling pathways in TPA-treated MCF-7 breast cancer cells,” Phytomedicine, vol. 50, pp. 35–42, 2018.
View at: Publisher Site | Google Scholar
F. Tian, M. Tong, Z. Li et al., “The effects of orientin on proliferation and apoptosis of T24 human bladder carcinoma cells occurs through the inhibition of nuclear factor-kappaB and the hedgehog signaling pathway,” Medical Science Monitor, vol. 25, pp. 9547–9554, 2019.
View at: Publisher Site | Google Scholar
T. Y. Wu, J. Liang, J. Y. Ai et al., “Mulberry ethanol extract and Rutin protect alcohol-damaged GES-1 cells by inhibiting the MAPK pathway,” Molecules, vol. 27, no. 13, Article ID 2713, 2022.
View at: Publisher Site | Google Scholar
Y. Y. Chen, X. J. Yan, X. H. Jiang, F. L. Lu, X. R. Yang, and D. P. Li, “Vicenin 3 ameliorates ECM degradation by regulating the MAPK pathway in SW1353 chondrocytes,” Experimental and Therapeutic Medicine, vol. 22, no. 6, p. 1461, 2021.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2023 Amir Taherkhani et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

676

Downloads

502

Citations